ReShape Lifesciences™ Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update
2021 Highlights and Accomplishments
- Achieved a significant, 20.4% increase in revenue, year-over-year
- Listed on Nasdaq via a successful merger with
Obalon Therapeutics , positioning ReShape as a major leader in the weight loss market - Raised
$46 million in cash to execute our business strategy - Eliminated all debt from the balance sheet including
$10.5 million of term debt with an institutional investor and the final$3.0 million obligation to Apollo Endosurgery for the purchase of the Lap-Band® - Ended the year with approximately
$23.0 million of cash and a current ratio of 4.2 - Ongoing, direct-to-consumer (DTC) marketing campaign highly successful, with surge in demand for Lap-Band procedures based on 331% increase in website traffic and 400% rise in doctor referrals
- Transitioned Lap-Band® manufacturing efforts to
U.S. based manufacturer, achieving significantly reduced costs and improved margins - Presented the Lap-Band Program and supportive reshapecare™ Virtual Health Coaching Platform to a large group of bariatric surgeons, allied health professionals and fellows, at the American Society for Metabolic and Bariatric Surgery’s (ASMBS)
Leadership Academy and re-UNITED Meeting - Launched an eCommerce platform and advanced line of supplements for bariatric surgery and medical weight loss patients, ReShape Optimize™ by
ProCare Health ®, available on ReShape Marketplace™ - Strengthened the operational and commercial teams with the addition of key personnel including
Michael Bordainick as Senior Vice President of Commercial Operations andAl Diaz as Vice President of Operations and Research and Development
“We believe we are at the precipice of reaping significant benefits from our robust, multi-tiered, direct-to-consumer marketing campaign, as we create an increased awareness for the advantages of our insurance reimbursed, next-generation Lap-Band program and suite of physician-led weight loss support solutions,” stated
Full Year 2021 Financial and Operating Results
Note for metrics analysis: For the year ended 2021, the Company experienced increases in sales and marketing, general and administrative, R&D, and total operating expenses due to the issuance of non-cash stock-based compensation for the first time since 2017, a loss on impairment of intangible assets and goodwill, and costs related to the acquisition of Obalon. Notably, non-cash stock-based compensation and the loss on impairment for the year ended
Revenue for the year ended December 31, 2021, was $13.6 million compared to
Gross Profit for the year ended
Sales and Marketing Expenses for the year ended December 31, 2021 were
General and Administrative Expenses were
Research and Development Expenses were
Total Operating Expenses were
Non-GAAP adjusted EBITDA loss was
Cash and Cash Equivalents were
Conference Call Information
Management will host a conference call to discuss ReShape’s financial and operational results today at
A replay will be available approximately two hours after the call, for one week. The replay number is 1-855-859-2056, conference ID 5376956. An archived replay will also be available at: https://ir.reshapelifesciences.com/events-and-presentations
About ReShape Lifesciences™
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our expectation that the marketing campaign should continue to promote increased demand for Lap-Band procedures and, thus, potentially a significant increase in revenues for ReShape. These and additional risks and uncertainties are described more fully in the company's filings with the
Non-GAAP Disclosures
In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.
Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this release have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
Adjusted EBITDA
Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, changes in fair value of liability warrants and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
CONTACTS
ReShape Lifesciences Investor Contact:
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Relations Contact:
(917)-633-6086
mmiller@rxir.com
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
2021 |
2020 |
||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 22,765 | $ | 2,957 | |||
Restricted cash | 50 | 50 | |||||
Accounts and other receivables | 2,815 | 2,620 | |||||
Inventory | 3,003 | 2,244 | |||||
Prepaid expenses and other current assets | 1,622 | 1,073 | |||||
Total current assets | 30,255 | 8,944 | |||||
Property and equipment, net | 1,454 | 584 | |||||
Operating lease right-of-use assets | 266 | 465 | |||||
Other intangible assets, net | 20,827 | 27,022 | |||||
Other assets | 1,456 | 46 | |||||
Total assets | $ | 54,258 | $ | 37,061 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 3,468 | $ | 3,655 | |||
Accrued and other liabilities | 3,169 | 3,630 | |||||
Warranty liability, current | 415 | 397 | |||||
Debt, current portion, net of deferred financing costs | — | 3,609 | |||||
Operating lease liabilities, current | 279 | 314 | |||||
Total current liabilities | 7,331 | 11,605 | |||||
Debt, noncurrent portion | — | 9,168 | |||||
Operating lease liabilities, noncurrent | — | 163 | |||||
Warranty liability, noncurrent | 300 | 1,022 | |||||
Deferred income taxes | 555 | 615 | |||||
Total liabilities | 8,186 | 22,573 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Preferred stock: | |||||||
Series B convertible preferred stock | — | — | |||||
Series C convertible preferred stock | — | 1 | |||||
Common stock | 18 | 4 | |||||
Additional paid-in capital | 622,906 | 529,431 | |||||
Accumulated deficit | (576,760 | ) | (514,827 | ) | |||
Accumulated other comprehensive loss | (92 | ) | (121 | ) | |||
Total stockholders’ equity | 46,072 | 14,488 | |||||
Total liabilities and stockholders’ equity | $ | 54,258 | $ | 37,061 | |||
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Year Ended |
|||||||
2021 | 2020 | ||||||
Revenue | $ | 13,600 | $ | 11,299 | |||
Cost of revenue | 5,252 | 5,037 | |||||
Gross profit | 8,348 | 6,262 | |||||
Operating expenses: | |||||||
Sales and marketing | 9,165 | 4,694 | |||||
General and administrative | 24,410 | 10,527 | |||||
Research and development | 2,522 | 3,498 | |||||
Loss on impairment of intangible assets and goodwill | 28,752 | — | |||||
Total operating expenses | 64,849 | 18,719 | |||||
Operating loss | (56,501 | ) | (12,457 | ) | |||
Other expense (income), net: | |||||||
Interest expense, net | 832 | 2,049 | |||||
Warrant expense | 2,813 | — | |||||
Loss on extinguishment of debt, net | 2,061 | 7,715 | |||||
Gain on foreign currency exchange, net | (168 | ) | (410 | ) | |||
Loss before income tax provision | (62,039 | ) | (21,811 | ) | |||
Income tax benefit | (106 | ) | (181 | ) | |||
Net loss | $ | (61,933 | ) | $ | (21,630 | ) | |
Net loss per share - basic and diluted: | |||||||
Net loss per share - basic and diluted | $ | (5.00 | ) | $ | (5.54 | ) | |
Shares used to compute basic and diluted net loss per share | 12,378,502 | 3,904,762 | |||||
The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the years ended
Years Ended |
|||||||
2021 | 2020 |
||||||
GAAP net loss | $ | (61,933 | ) | $ | (21,630 | ) | |
Adjustments: | |||||||
Interest expense, net: | 832 | 2,049 | |||||
Income tax benefit | (106 | ) | (181 | ) | |||
Depreciation and amortization | 1,971 | 1,667 | |||||
Stock-based compensation expense | 12,752 | 1,323 | |||||
Loss on impairment of intangible assets and goodwill | 28,752 | — | |||||
Loss on extinguishment of debt | 2,061 | 7,715 | |||||
Warrant expense | 2,813 | — | |||||
Professional fees incurred in connection with the Obalon merger | 2,277 | — | |||||
Non-GAAP loss | $ | (10,581 | ) | $ | (9,057 | ) |
Source: ReShape Lifesciences Inc